Literature DB >> 1460419

Predominance of fetal type DJH joining in young children with B precursor lymphoblastic leukemia as evidence for an in utero transforming event.

R Wasserman1, N Galili, Y Ito, B A Reichard, S Shane, G Rovera.   

Abstract

The presence of N sequences in the complementarity determining region 3 (CDR3) of the rearranged immunoglobulin H chain is developmentally regulated: N regions are generally present in the DJH joinings of adult B cells but are often absent in fetal B cells. Analysis of the CDR3 in 61 B precursor acute lymphoblastic leukemias indicated that 87.5% of the leukemias obtained from children < or = 3 yr old lacked N regions at the DJH junction. In contrast, in children > 3 yr old, only 11.1% of the leukemias lacked N regions at this junction, a frequency similar to what we have observed in B cells from children and adults. These findings suggest that the majority of leukemias presenting within the first 3 yr of age arise from an in utero transforming event.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1460419      PMCID: PMC2119455          DOI: 10.1084/jem.176.6.1577

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

Review 1.  Human immunoglobulin heavy-chain variable region genes: organization, polymorphism, and expression.

Authors:  V Pascual; J D Capra
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

2.  Junctional sequences of T cell receptor gamma delta genes: implications for gamma delta T cell lineages and for a novel intermediate of V-(D)-J joining.

Authors:  J J Lafaille; A DeCloux; M Bonneville; Y Takagaki; S Tonegawa
Journal:  Cell       Date:  1989-12-01       Impact factor: 41.582

3.  RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination.

Authors:  M A Oettinger; D G Schatz; C Gorka; D Baltimore
Journal:  Science       Date:  1990-06-22       Impact factor: 47.728

Review 4.  Molecular characterization of the lymphoid V(D)J recombination activity.

Authors:  T K Blackwell; F W Alt
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

5.  Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment.

Authors:  M Yamada; R Wasserman; B Lange; B A Reichard; R B Womer; G Rovera
Journal:  N Engl J Med       Date:  1990-08-16       Impact factor: 91.245

6.  The pattern of joining (JH) gene usage in the human IgH chain is established predominantly at the B precursor cell stage.

Authors:  R Wasserman; Y Ito; N Galili; M Yamada; B A Reichard; S Shane; B Lange; G Rovera
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

7.  Clonal proliferation unlinked to terminal deoxynucleotidyl transferase synthesis in thymocytes of young mice.

Authors:  E Rothenberg; D Triglia
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

Review 9.  Immunologic classification of leukemia and lymphoma.

Authors:  K A Foon; R F Todd
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

10.  Lack of N regions in fetal and neonatal mouse immunoglobulin V-D-J junctional sequences.

Authors:  A J Feeney
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

View more
  12 in total

1.  Establishment of a novel B cell clonality analysis using single-strand conformation polymorphism of immunoglobulin light chain messenger signals.

Authors:  S Shiokawa; J Nishimura; K Ohshima; N Uike; K Yamamoto
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

2.  Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia.

Authors:  Joseph L Wiemels; Brian C Leonard; Yunxia Wang; Mark R Segal; Stephen P Hunger; Martyn T Smith; Vonda Crouse; Xiaomei Ma; Patricia A Buffler; Sharon R Pine
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

Review 3.  Big babies and infant leukemia: a role for insulin-like growth factor-1?

Authors:  J A Ross; J P Perentesis; L L Robison; S M Davies
Journal:  Cancer Causes Control       Date:  1996-09       Impact factor: 2.506

4.  Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways.

Authors:  Eva Sanz; Norman Muñoz-A; Jorge Monserrat; Ana Van-Den-Rym; Pedro Escoll; Ismael Ranz; Melchor Alvarez-Mon; Antonio de-la-Hera
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

5.  Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia.

Authors:  A M Ford; C A Bennett; C M Price; M C Bruin; E R Van Wering; M Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

Review 6.  Perspectives on the causes of childhood leukemia.

Authors:  Joseph Wiemels
Journal:  Chem Biol Interact       Date:  2012-02-02       Impact factor: 5.192

7.  Comparable profiles of the immunoglobulin heavy chain complementarity determining region (CDR)-3 in CD5+ and CD5- human cord blood B lymphocytes.

Authors:  H Kiyoi; K Naito; R Ohno; T Naoe
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

8.  Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma.

Authors:  D D Biggs; P Kraj; J Goldman; L Jefferies; C Carchidi; K Anderson; L E Silberstein
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

9.  Mechanistic constraints on diversity in human V(D)J recombination.

Authors:  G H Gauss; M R Lieber
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

Review 10.  Occurrence of ²¹⁰Po and biological effects of low-level exposure: the need for research.

Authors:  Ralph L Seiler; Joseph L Wiemels
Journal:  Environ Health Perspect       Date:  2012-04-26       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.